Editorial scope: This guide addresses analytical evidence, documentation, and research-procurement literacy. Conclusions are limited to the records and methods discussed.

Start with the naming: VIP is a molecule, not a single product

Vasoactive intestinal peptide, usually shortened to VIP, is an endogenous 28-amino-acid signaling peptide. It was first isolated from porcine small intestine in 1970, but later work established that VIP is distributed well beyond the gastrointestinal tract, including neural, pulmonary, immune, and vascular tissues. The name therefore describes one signaling molecule with many context-dependent biological roles; it does not describe one uniform experimental effect.

Aviptadil is the nonproprietary name used for synthetic VIP. FDA's substance record lists aviptadil and human VIP as mappings for the same 28-residue sequence. That identity connection is useful, but it does not make every material labeled VIP equivalent to a clinical aviptadil formulation. Sequence, terminal chemistry, counterion, impurities, concentration, excipients, container, stability, and route-specific formulation can all change what was actually studied.

This article reviews VIP and aviptadil as research subjects. It does not provide a protocol, dose, route, treatment recommendation, or evidence that a supplier product is suitable for human or veterinary use.

  • VIP: the endogenous 28-amino-acid peptide
  • Aviptadil: the nonproprietary name for synthetic VIP used in drug-development records
  • Clinical formulation: a defined investigational or authorized product with its own manufacturing and quality controls
  • Research-vendor material: a separately documented lot that cannot borrow the evidence or status of a clinical product

Molecular identity comes before biological interpretation

The original isolation paper described a 28-residue peptide with broad physiological activity. A later study isolated human VIP from colonic tissue and reported an amino-acid composition and N-terminus matching the porcine and bovine forms then known. Modern FDA substance records provide the full sequence and identify the C-terminal amide. Those details matter because a missing residue, an unreported terminal form, oxidation, deamidation, or another degradation product can change receptor activity or analytical behavior.

VIP belongs to the secretin-family peptide system and is related to pituitary adenylate cyclase-activating polypeptide, or PACAP. Related ligands can share receptor activity, so a biological response is not an identity test. A vial cannot be confirmed as VIP because it produces a nonspecific response in a cell assay. Orthogonal chemical evidence is needed to connect the material to the expected sequence and molecular mass.

For procurement review, the useful starting questions are direct: what exact sequence and terminal chemistry are claimed, which salt or counterion is present, what identity method was used, does the observed mass agree with the stated form, and does the report identify the offered lot?

Cell evidence: VPAC receptors and signaling are well established

VIP is best known for activating the class B G-protein-coupled receptors VPAC1 and VPAC2. PACAP can also activate those receptors, while the related PAC1 receptor generally favors PACAP. Receptor expression varies by tissue and cell state, which helps explain why VIP can be associated with smooth-muscle relaxation, secretion, immune signaling, and neural effects in different experimental systems.

In a primary receptor study, investigators expressed the human VIP1 receptor, now called VPAC1, in stable cell lines. VIP produced concentration-dependent increases in cyclic AMP and intracellular calcium in the engineered cells, while untransfected cells had minimal binding or response. Native receptor-bearing intestinal cells showed similar signaling. This is strong mechanistic evidence that a defined receptor can couple VIP exposure to more than one intracellular pathway.

Mechanistic evidence is not clinical evidence. Engineered cell lines can overexpress receptors, use simplified media, and omit metabolism, tissue barriers, compensatory signaling, and exposure patterns present in an organism. A response in a receptor assay establishes biological activity under that assay's conditions; it does not establish a therapeutic effect, a safe exposure, or equivalence between two preparations.

Animal evidence: broad effects, but model dependence is substantial

Animal studies have examined VIP across vascular, pulmonary, gastrointestinal, metabolic, and immune models. For example, selective VPAC agonists and VIP reduced inflammatory mediators in a mouse endotoxemia model, supporting the idea that VIP-receptor signaling can modify inflammatory pathways under defined experimental conditions. Other studies have used isolated vessels, organ preparations, or whole-animal models to investigate vasodilation and smooth-muscle responses.

These findings help map possible mechanisms, but they are unusually easy to overgeneralize. VIP is rapidly degraded, receptor distribution differs across tissues and species, and measured outcomes can depend on formulation and exposure route. A result from a mouse inflammatory challenge or an isolated porcine artery cannot establish benefit in a human disease, and it does not validate a commercial research lot.

The test article also matters. Native VIP, aviptadil, receptor-selective analogs, and formulated investigational products should not be pooled as though they were interchangeable. A useful evidence table records the exact molecule, species, model, formulation, comparator, endpoint, and observation time.

Human evidence begins with physiology and small proof-of-concept studies

Human research confirms that VIP-related signaling can produce measurable physiological effects, but the strongest interpretation depends on the specific population and product. In a 20-person catheterization study involving several forms of chronic pulmonary hypertension, inhaled aviptadil produced a small, short-lived pulmonary vasodilator effect. Only a subset reached the study's larger-response threshold, and the authors called for further studies.

That experiment is useful pharmacology evidence: a defined exposure produced a measurable hemodynamic signal under close clinical observation. It is not proof of durable clinical benefit. The sample was small and heterogeneous, the observation window was short, and the study was not designed to establish long-term outcomes.

This distinction is central to VIP research. A biomarker, receptor response, or acute physiological change can support target engagement without demonstrating that the intervention improves how participants feel, function, or survive.

Randomized aviptadil trials produced mixed and ultimately negative efficacy evidence

Aviptadil was studied in randomized trials during the COVID-19 pandemic because preclinical findings suggested effects on pulmonary cells, inflammation, and surfactant biology. One multicenter placebo-controlled trial enrolled 196 participants with critical COVID-19 respiratory failure. Its prespecified primary endpoint, being alive and free from respiratory failure at day 60, was not statistically significant. The publication reported a survival signal and exploratory subgroup findings, but those secondary observations cannot replace a missed primary endpoint.

A larger NIH-involved phase 3 platform trial provides a more decisive test. Among 461 treated participants in the aviptadil comparison, the odds ratio for a better day-90 outcome was 1.11 with a 95% confidence interval of 0.80 to 1.55 and a p value of 0.54. Day-90 mortality was 38 percent with aviptadil and 36 percent with placebo. The monitoring board recommended stopping the comparison for futility, and the investigators concluded that aviptadil did not improve the primary outcome, survival, or other efficacy endpoints in that setting.

These trials do not prove that VIP biology is unimportant. They show why a plausible mechanism and earlier signal must be tested against adequately controlled clinical outcomes. They also apply to specific intravenous aviptadil products, populations, and trial conditions; they do not settle every possible research question involving VIP.

Safety observations are product- and setting-specific

The larger phase 3 trial reported that flushing, hypotension, and diarrhea were more common in the aviptadil group. Infusion interruptions and pauses due to adverse events were also more frequent. Those findings belong to a monitored hospital trial using a defined investigational product and cannot be converted into instructions for handling or using supplier material.

It is equally incorrect to infer safety from endogenous status. The body produces VIP locally and transiently, but an externally supplied material can create different concentrations, distribution, duration, impurities, and degradation products. Endogenous does not mean automatically safe, and a clinical safety record does not transfer to an unrelated lot or formulation.

For research planning, safety observations help define unresolved questions and assay controls. They do not establish a general safe level, a self-experimentation framework, or suitability outside the conditions actually studied.

Regulatory status: identification and orphan designation are not approval

FDA's substance database assigns aviptadil a Unique Ingredient Identifier and lists its sequence and synonyms. The same record explicitly notes that a UNII does not imply regulatory review or approval. A database identity entry is therefore useful for naming and substance matching, not for claiming an approved use.

FDA has granted aviptadil orphan-drug designations for pulmonary arterial hypertension and sarcoidosis. FDA's own designation records state that aviptadil was not approved for either orphan indication. Orphan designation can support development for a rare condition, but it is not marketing approval and does not establish efficacy.

As reviewed on November 9, 2026, VIP/aviptadil is not an FDA-approved drug in the United States. Research suppliers should not imply that a catalog material inherits an investigational sponsor's status, an orphan designation, or evidence generated with a separately manufactured clinical product.

What the evidence does and does not establish

The evidence base is strongest for molecular identity, receptor pharmacology, and the existence of context-dependent physiological effects. It includes extensive preclinical work and several human experiments. It does not establish broad therapeutic benefit. The largest controlled aviptadil trial in critical COVID-19 respiratory failure was negative for its primary clinical outcome.

Important unresolved questions include how formulation and degradation affect observed activity, which tissues and disease states are most relevant to VPAC1 versus VPAC2 signaling, whether receptor-selective analogs can improve the benefit-risk profile, and which preclinical findings can survive controlled human testing. Answers will require defined test articles, fit-for-purpose assays, transparent protocols, and outcome-appropriate studies.

A responsible summary should therefore avoid two opposite errors: dismissing a well-established signaling peptide because one clinical program failed, or treating broad biological activity as proof of a useful intervention.

  • Established: VIP is a defined endogenous 28-residue peptide with reproducible VPAC receptor activity
  • Supported: cell and animal models show diverse, context-dependent signaling effects
  • Limited: small human studies demonstrate acute physiological signals in selected settings
  • Not established: general clinical benefit, broad safety, or equivalence of supplier material to clinical aviptadil
  • Negative high-level evidence: a large phase 3 trial did not improve outcomes in critical COVID-19 respiratory failure

Supplier documentation answers a different question from scientific literature

A PubMed paper can explain what a characterized research material did in a study. It cannot establish what is inside a supplier's current vial. Supplier documentation should instead connect a specific lot to defined identity, purity, quantity, and stability evidence. Microbiological attributes are separate and cannot be inferred from chemical tests.

For VIP, identity review should account for the 28-residue sequence, C-terminal amide, expected molecular form, and any declared counterion. A mass-spectrum result can support molecular identity when the observed ions agree with the stated form. A chromatographic purity result can describe detected components under one method, but an area percentage alone does not establish identity or net peptide content.

VIP's susceptibility to degradation makes sample history especially relevant. A stability claim should name the tested formulation, container, conditions, time points, analytical method, and acceptance criteria. Generic handling language or a single release test is not a stability program.

A research-procurement checklist for VIP

Use the literature to define the molecule and the question, then use lot-specific records to evaluate the offered material. Keep the two evidence tracks separate in your review file. If a record is missing, mark the attribute as not established rather than converting silence into a pass or fail.

Price, presentation, and an attractive purity number are not substitutes for traceability. Compare suppliers only after confirming that listings refer to the same sequence, amount, form, and level of documentation.

  • Naming: does the listing state VIP, vasoactive intestinal peptide, or aviptadil, and does it define what that name means?
  • Sequence: is the complete 28-residue sequence and C-terminal amide specified?
  • Form: are counterion, salt form, excipients, and presentation disclosed?
  • Identity: does orthogonal evidence connect the observed result to the expected molecular form?
  • Purity and quantity: are chromatographic composition and net peptide content treated as separate attributes?
  • Traceability: do product, lot, report identifier, laboratory, and dates match?
  • Stability: are claims supported by time-point data for the actual formulation and container?
  • Scope: are chemical results kept separate from sterility, endotoxin, and suitability claims?

FAQ: Are VIP and aviptadil the same thing?

Aviptadil is the nonproprietary name for synthetic VIP and FDA's substance record maps it to the human VIP sequence. However, a clinical aviptadil product and a research material labeled VIP are not automatically equivalent. Formulation, purity, quantity, excipients, manufacturing controls, stability, and lot documentation must be evaluated separately.

FAQ: Does a VIP purity result prove the vial contains aviptadil?

No. A chromatographic area percentage describes detector response under a particular method. It does not identify the main peak by itself and does not establish net peptide content. Identity requires suitable orthogonal evidence, and the report must be traceable to the offered lot.

FAQ: Do aviptadil trials validate research-supplier VIP products?

No. Clinical trials evaluate defined investigational products under controlled manufacturing, formulation, storage, and protocol conditions. Their findings cannot validate the identity, quality, safety, or suitability of an unrelated supplier lot. Supplier documentation and scientific evidence answer different questions.

Sources and further reading

Primary and standards-based sources used to frame this educational overview:

Explore related resources

Peptide Due Diligence Research Brief

Keep the evidence in view.

Receive concise briefings on analytical testing, documentation quality, supplier transparency, and new additions to the research library.

By subscribing, you agree to receive PDD research emails. Unsubscribe at any time.

Already subscribed? Get your free field guide.

Continue your due diligence